Drug repositioning for esophageal squamous cell carcinoma

Drug repositioning for esophageal squamous cell carcinoma

Esophageal cancer (EC) remains a significant challenge globally, having the 8th highest incidence and 6th highest mortality worldwide. Esophageal squamous cell carcinoma (ESCC) is the most common form of EC in Asia. Crucially, more than 90% of EC cases in China are ESCC. The high mortality rate of E...

Full description

Bibliographic Details
Main Authors:	Adam N. Bennett, Rui Xuan Huang, Qian He, Nikki P. Lee, Wing-Kin Sung, Kei Hang Katie Chan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Genetics
Subjects:	drug repositioning drug repurposing esophageal squamous cell carcinoma ESCC treatment cancer biology
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2022.991842/full

Similar Items

Lung adenocarcinoma-related target gene prediction and drug repositioning
by: Rui Xuan Huang, et al.
Published: (2022-08-01)

Drug Repositioning for Hand, Foot, and Mouth Disease
by: Ran Yan, et al.
Published: (2022-12-01)

Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs
by: Daniele Parisi, et al.
Published: (2020-01-01)

Changing Trends in Computational Drug Repositioning
by: Jaswanth K. Yella, et al.
Published: (2018-06-01)

Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents
by: Sha Zhu, et al.
Published: (2022-01-01)

Characterization of Esophageal Microbiota in Patients With Esophagitis and Esophageal Squamous Cell Carcinoma
by: Zongdan Jiang, et al.
Published: (2021-11-01)

Drug Repositioning for Effective Prostate Cancer Treatment
by: Beste Turanli, et al.
Published: (2018-05-01)

Microarray Analysis of Radioresistance-associated Genes in Esophageal Squamous Cell Carcinoma
by: ZHU Qingshan, et al.
Published: (2019-03-01)

Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization
by: Héctor Hernández-Parra, et al.
Published: (2022-09-01)

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes
by: Katharine Yu, et al.
Published: (2023-06-01)

Integrative rare disease biomedical profile based network supporting drug repurposing or repositioning, a case study of glioblastoma
by: Erin McGowan, et al.
Published: (2023-09-01)

Prevalence and Association of Human Papillomavirus with Esophageal Squamous Cell Carcinoma in Iran: A Systematic Review and Meta-Analysis
by: Bashir MOHAMMADPOUR, et al.
Published: (2019-07-01)

Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates
by: Joana M. O. Santos, et al.
Published: (2021-10-01)

Occupational risks of esophageal cancer in Taiwanese men
by: Shih-Hui Huang, et al.
Published: (2012-12-01)

Systematic drug repositioning through mining adverse event data in ClinicalTrials.gov
by: Eric Wen Su, et al.
Published: (2017-03-01)

Current advances and future perspectives on the functional roles and clinical implications of circular RNAs in esophageal squamous cell carcinoma: more influential than expected
by: Chenxi Ju, et al.
Published: (2022-06-01)

Computational drug repositioning based on side-effects mined from social media
by: Timothy Nugent, et al.
Published: (2016-02-01)

Prospects for repurposing CNS drugs for cancer treatment
by: Mohamed Abdelaleem, et al.
Published: (2019-04-01)

Clinical value of station 4R node dissection in esophageal squamous cell carcinoma
by: Xin-ye Wang, et al.
Published: (2023-12-01)

Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy
by: Chia-Hsin Lin, et al.
Published: (2020-03-01)

Expression of fibronectin in esophageal squamous cell carcinoma and its role in migration
by: Jiefei Xiao, et al.
Published: (2018-10-01)

Global research trend of esophageal squamous cell carcinoma from 2012 to 2022: a bibliometric analysis
by: Zehua Zhang, et al.
Published: (2022-08-01)

Plasma-metabolite-based machine learning is a promising diagnostic approach for esophageal squamous cell carcinoma investigation
by: Zhongjian Chen, et al.
Published: (2021-08-01)

Development and Validation of a Ferroptosis-Related Gene Signature and Nomogram for Predicting the Prognosis of Esophageal Squamous Cell Carcinoma
by: Jiecheng Ye, et al.
Published: (2021-10-01)

Elucidation of bioinformatic-guided high-prospect drug repositioning candidates for DMD via Swanson linking of target-focused latent knowledge from text-mined categorical metadata
by: J. Wes Ulm, et al.
Published: (2023-08-01)

Drug Repositioning for Refractory Benign Tumors of the Central Nervous System
by: Ryota Tamura
Published: (2023-08-01)

Tackling the Behavior of Cancer Cells: Molecular Bases for Repurposing Antipsychotic Drugs in the Treatment of Glioblastoma
by: Michele Persico, et al.
Published: (2022-01-01)

An FDA-Drug Library Screen for Compounds with Bioactivities against Meticillin-Resistant Staphylococcus aureus (MRSA)
by: Qiu Ying Lau, et al.
Published: (2015-10-01)

Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer
by: Zhe Zhang, et al.
Published: (2023-04-01)

Capn4 promotes esophageal squamous cell carcinoma metastasis by regulating ZEB1 through the Wnt/β‐catenin signaling pathway
by: Yun‐Long Zhao, et al.
Published: (2019-01-01)

Transcriptomics based multi-dimensional characterization and drug screen in esophageal squamous cell carcinoma
by: Yin Li, et al.
Published: (2021-08-01)

AURKA knockdown inhibits esophageal squamous cell carcinoma progression through ferroptosis
by: Yuan Mi, et al.
Published: (2024-04-01)

Identifying LATS2 as a prognostic biomarker relevant to immune infiltrates in human esophageal squamous cell carcinoma
by: Minqi Zhu, et al.
Published: (2022-09-01)

circGSK3β promotes metastasis in esophageal squamous cell carcinoma by augmenting β-catenin signaling
by: Xueting Hu, et al.
Published: (2019-11-01)

Optimal Range of Lymphadenectomy in Pathological Stage T1 and T2 Esophageal Squamous Cell Carcinoma
by: Hansheng Wu, et al.
Published: (2021-05-01)

Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights
by: Stavros P. Papadakos, et al.
Published: (2024-03-01)

Drug Repurposing Applications to Overcome Male Predominance via Targeting G2/M Checkpoint in Human Esophageal Squamous Cell Carcinoma
by: Yin Yin, et al.
Published: (2022-11-01)

Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial)
by: Chengzhi Ding, et al.
Published: (2023-12-01)

Abdominal lymph node metastasis in non-surgical esophageal squamous cell carcinoma: prognostic significance and a novel staging strategy
by: Zongxing Zhao, et al.
Published: (2023-10-01)

Predictive Value of LINC01133 for Unfavorable Prognosis was Impacted by Alcohol in Esophageal Squamous Cell Carcinoma
by: Xian-Zi Yang, et al.
Published: (2018-07-01)